Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies.
To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and Etoposide (VP-16) as a purging agent for myeloma cells in bone marrow ex-vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal bone marrow (BM) cells were treated at different concentrations of 4-HC, VP-16. In separate experiments, LAK cells or antibodies were also used to treat the above cell lines. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal bone marrow cells at a 4-HC concentration of 60 mumol/l. Under similar conditions, approximately 1% of normal BM myeloid progenitor granulocyte-macrophage colony forming cells (CFU-GM) survived. The results with LAK cells and antibodies were also encouraging. These observations support the use of various purging methods for myeloma cells for autologous bone marrow transplantation.
Gulati
S C
SC
Shimazaki
C
C
Lemoli
R M
RM
Atzpodien
J
J
Clarkson
B D
BD
D000911:Antibodies, Monoclonal / Q000276:immunology*; D002469:Cell Separation / Q000379:methods*; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D003602:Cytotoxicity, Immunologic; D005047:Etoposide / Q000494:pharmacology*; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D008280:Magnetics; D009101:Multiple Myeloma / Q000473:pathology*; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014410:Tumor Stem Cell Assay
D000911:Antibodies, Monoclonal; D005047:Etoposide; D003520:Cyclophosphamide; C011272:perfosfamide